Office Action Predictor
Application No. 17/289,518

AMORPHOUS COMPOUNDS OF FORMULA (I) AND AMORPHOUS COMPOUNDS OF FORMULA (I) SALTS

Non-Final OA §112
Filed
Apr 28, 2021
Examiner
PECKHAM, RICHARD GRANT
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
H. Lundbeck A/S
OA Round
3 (Non-Final)
69%
Grant Probability
Favorable
3-4
OA Rounds
3y 3m
To Grant
88%
With Interview

Examiner Intelligence

69%
Career Allow Rate
79 granted / 115 resolved
Without
With
+19.0%
Interview Lift
avg trend
3y 3m
Avg Prosecution
44 pending
159
Total Applications
career history

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
28.4%
-11.6% vs TC avg
§102
14.3%
-25.7% vs TC avg
§112
29.6%
-10.4% vs TC avg
Black line = Tech Center average estimate • Based on career data

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Response to Amendment The amendment filed 1/28/2025 has been entered. Claims 1, 6-13, 15-18, and 20-26 remain pending in the application. Applicant’s amendments to the Claims have overcome every objection and rejection previously set forth in the Final Office Action mailed 11/29/2024. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied and constitute the complete set presently being applied to the instant application. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/27/2025 has been entered. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 16 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. The phrase "including" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Is “treatment-resistant schizophrenia” merely exemplary of a type schizophrenia or limiting the scope to that particular narrower embodiment? Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 11 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The “comprising” language is inclusive rather than exclusive and therefore does not further limit the scope of the polymers of Claim 10, upon which Claim 11 depends. Claim 11 does not narrow the scope of Claim 10. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter Claims 1, 6-10, 12-13, 15, 17-18, and 20-26 are allowed. The following is an examiner’s statement of reasons for allowance: the closest prior art of Jacobsen fails to teach the amorphous form of the claimed compound (compound XV in Jacobsen: PNG media_image1.png 136 92 media_image1.png Greyscale ) or the unexpected stability of the amorphous forms as evidenced by the actual elevated temperatures at which the claimed free base and salt are stable as compared to the calculated values. (See Final Action 11/29/2024, Page 4; Figs. 1-2; Specification, Page 27-28, Example 1; and Remarks 11/01/2024, Page 16). Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.” Conclusion Claims 1, 6-10, 12-13, 15, 17-18, and 20-26 are allowed. Claims 11 and 16 are rejected. Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G. Peckham whose telephone number is (703)756-4621. The examiner can normally be reached 7:30am - 4:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached on (571) 270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RICHARD GRANT PECKHAM/Examiner, Art Unit 1627 /Kortney L. Klinkel/Supervisory Patent Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Apr 28, 2021
Application Filed
Apr 29, 2024
Non-Final Rejection — §112
Nov 01, 2024
Response Filed
Nov 20, 2024
Final Rejection — §112
Jan 28, 2025
Response after Non-Final Action
Feb 27, 2025
Request for Continued Examination
Mar 02, 2025
Response after Non-Final Action
Mar 07, 2025
Examiner Interview (Telephonic)
Aug 06, 2025
Non-Final Rejection — §112
Apr 13, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology. Study what changed to get past this examiner.

Patent 12595243
MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE
2y 5m to grant Granted Apr 07, 2026
Patent 12583859
PRMT5 INHIBITORS AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12583823
CRYSTAL FORM OF DAPRODUSTAT, PREPARATION METHOD THEREFOR AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12570614
Phenyl Amino Pyrimidine Compounds and Uses Thereof
2y 5m to grant Granted Mar 10, 2026
Patent 12569452
OPTHALMIC COMPOSITIONS COMPRISING F6H8
2y 5m to grant Granted Mar 10, 2026

AI Strategy Recommendation

Click below to generate an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
69%
Grant Probability
88%
With Interview (+19.0%)
3y 3m
Median Time to Grant
High
PTA Risk
Based on 115 resolved cases by this examiner